Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 3412345...102030...Last »

Soaring costs, loss of benefits top Americans’ healthcare worries: Reuters/Ipsos poll

Americans listed healthcare as the most important problem facing the country, according to Reuters/Ipsos polling.

Read More »

U.S. drug prices hit by insurer tactic against copay assistance: analysis

A recently adopted tactic by U.S. health plans to limit the financial assistance drugmakers provide directly to consumers for prescription medicines is taking a toll on drug prices, according to a new analysis.

Read More »

J&J’s Stelara Improves Crohn’s In Two-Year Study

The Janssen Pharmaceutical Companies, part of Johnson & Johnson, presented two-year data from its IM-UNITI trial of Stelara (ustekinumab) in Crohn’s disease.

Read More »

Trump assails high drug prices, avoids direct hit on industry

U.S. President Donald Trump blasted drugmakers and healthcare “middlemen” for making prescription medicines unaffordable for Americans, but healthcare stocks rose as his administration avoided aggressive direct measures to cut prices.

Read More »

In Europe, Mylan’s rivals try to plug EpiPen shortages

European makers of emergency allergy treatments are stepping up production of alternative life-saving adrenaline shots to try to fill intermittent shortages of Mylan’s market-leading EpiPen injection.

Read More »

Regeneron/Sanofi to cut price of heart drug

Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said.

Read More »

China to cut import value-added tax on cancer drugs from May 1, 2018

China will cut the import value-added tax on cancer drugs to 3 percent from May 1, the Finance Ministry said.

Read More »

As cancer drug prices climb, value not keeping pace

The cost of new anti-cancer drugs increased more than five-fold from 2006 to 2015, but a new analysis suggests that cancer patients and insurers may be getting less for their money.

Read More »

Report Links Nuplazid to High Number of Deaths

Shares of Acadia Pharmaceuticals were down following a CNN report that raises concerns over a number of deaths and adverse events linked to the company’s Parkinson’s disease drug Nuplazid.

Read More »

Roche shares drop after deaths of patients taking Hemlibra

Roche’s shares dropped after the Swiss drugmaker told U.S.-based hemophilia advocacy groups that five patients treated with its medicine Hemlibra had died, while maintaining that the therapy was not the cause of the deaths.

Read More »

Tokyo court rejects Shire claim against Roche hemophilia drug

A Tokyo court ruled that Shire’s claim against Swiss drugmaker Roche’s new Hemlibra hemophilia medicine should be dismissed, Roche’s Japanese subsidiary Chugai said.

Read More »

GSK wins new reprieve as Hikma’s generic Advair delayed again

The FDA insisted Hikma conduct a further clinical study evaluating its generic version of GlaxoSmithKline’d blockbuster lung drug.

Read More »

Regeneron/Sanofi heart drug succeeds in major trial

A potent, expensive cholesterol drug sold by Regeneron Pharmaceuticals and Sanofi significantly reduced major adverse heart events in a huge study.

Read More »

Biogen, AbbVie Voluntarily Pull Multiple Sclerosis Drug Off The Market

Biogen and AbbVie voluntarily pulled their Zinbryta for relapsing multiple sclerosis (MS) off the market after safety concerns.

Read More »

U.S. health officials reverse stance on flu vaccine

An advisory committee of the U.S. CDC recommended the use of AstraZeneca’s FluMist Quadrivalent vaccine in the upcoming flu season, reversing its earlier position.

Read More »

Special Feature – Value of Medicines: The value equation

As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.

Read More »

Value of Medicines: PBM waste makes valuable drugs valueless

On Oct. 28, 2016, my mother, Joan Biamonte, died of complications from metastatic carcinoma of the lung. Despite having her original tumor characterized and going through a regimen of chemotherapy allegedly tailored to her tumor type, her cancer proliferated and spread into her liver and brain.

Read More »

U.S. healthcare spending to climb 5.3 percent in 2018: agency

United States health spending is projected to rise 5.3 percent in 2018, reflecting rising prices of medical goods and services and higher Medicaid costs.

Read More »

Xtandi delays prostate cancer spread in early-stage disease

Use of Xtandi in early-stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 percent compared with hormone therapy alone.

Read More »

Novartis says Entresto could become $5 billion a year blockbuster drug

A Novartis executive said the Swiss company’s heart failure medicine Entresto could be used more widely in the future.

Read More »

Page 1 of 3412345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review


Ad Right Bottom

Main Navigation